Transcranial Direct Current Stimulation Therapy for Bipolar Depression
Primary Purpose
Depression, Bipolar, Bipolar Disorder, Mood Disorders
Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Transcranial Direct Current Stimulation
Sponsored by
About this trial
This is an interventional treatment trial for Depression, Bipolar
Eligibility Criteria
Inclusion Criteria:
- diagnosis of bipolar disorder based on DSM-5 criteria
- minimum score of 18 on the MADRS
- being on a stable dosage of mood stabilizing medication for a minimum of two weeks
Exclusion Criteria:
- comorbid psychiatric disorder
- significant risk of suicide or self harm
- any contraindications to tDCS, including implanted electronic medical devices
- history of epilepsy
Sites / Locations
- University of East LondonRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Device: transcranial direct current stimulation
Arm Description
6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
Outcomes
Primary Outcome Measures
Clinical response [ Time Frame: At 6 weeks following course of tDCS treatment ]
As measured by clinician-rated MADRS score improvement of >= 50% following the course of tDCS treatment
Secondary Outcome Measures
Full Information
NCT ID
NCT05436613
First Posted
June 23, 2022
Last Updated
June 23, 2022
Sponsor
University of East London
Collaborators
University College, London, King's College London, Technische Universität Dresden
1. Study Identification
Unique Protocol Identification Number
NCT05436613
Brief Title
Transcranial Direct Current Stimulation Therapy for Bipolar Depression
Official Title
Community-based Transcranial Direct Current Stimulation Treatment for Bipolar Depression
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2022 (Actual)
Primary Completion Date
May 2023 (Anticipated)
Study Completion Date
May 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of East London
Collaborators
University College, London, King's College London, Technische Universität Dresden
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Bipolar disorder is a severe and disabling disorder. The course of illness is often progressive but is highly heterogeneous between individuals and within the lifetime for an individual. The most common treatments are medications. However, for many individuals, combinations of medications are often required, and full recovery is infrequent.
The novel brain stimulation treatment, transcranial direct current stimulation (tDCS), is a potential first-line treatment for bipolar depression. The present research question is whether tDCS can be provided as a home-based treatment for bipolar depression for adults with bipolar disorder.
Detailed Description
The novel brain stimulation treatment, transcranial direct current stimulation (tDCS), is a potential first-line treatment for bipolar disorder. tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a headband worn over the forehead with two electrodes, which are small metal discs, where the current comes from. tDCS does not directly stimulate brain cells to cause a seizure like electroconvulsive therapy (ECT) and it does not induce brain cells to discharge like transcranial magnetic stimulation (TMS).
Clinical studies have shown that tDCS treatment could help to improve the symptoms of depression. The main side effects have been redness, skin irritation or sensations (itching, tingling or burning) under the electrodes. Less commonly reported side effects include headache or tiredness. tDCS is a portable and safe treatment.
The studies to date have mostly looked at tDCS treatment which has been provided in a research setting. This is a problem because the treatment requires daily sessions for several weeks which could limit whether individuals would be able to go every day. As tDCS is a portable and safe treatment, it could be provided in the community.
The present study is a proof-of-concept trial to assess the efficacy, acceptability and safety of tDCS treatment for bipolar depression within a community-based setting.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Bipolar, Bipolar Disorder, Mood Disorders, Mental Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
68 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Device: transcranial direct current stimulation
Arm Type
Experimental
Arm Description
6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
Intervention Type
Device
Intervention Name(s)
Transcranial Direct Current Stimulation
Intervention Description
tDCS at 2mA in 30 minute sessions for 5 sessions per week for 3 weeks and then 2 sessions per week for 3 weeks.
Primary Outcome Measure Information:
Title
Clinical response [ Time Frame: At 6 weeks following course of tDCS treatment ]
Description
As measured by clinician-rated MADRS score improvement of >= 50% following the course of tDCS treatment
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diagnosis of bipolar disorder based on DSM-5 criteria
minimum score of 18 on the MADRS
being on a stable dosage of mood stabilizing medication for a minimum of two weeks
Exclusion Criteria:
comorbid psychiatric disorder
significant risk of suicide or self harm
any contraindications to tDCS, including implanted electronic medical devices
history of epilepsy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cynthia Fu, MD, PhD
Phone
0208 223 4119
Email
C.Fu@uel.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cynthia Fu, MD, PhD
Organizational Affiliation
University of East London
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of East London
City
London
ZIP/Postal Code
E16 2RD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cynthia Fu, MD, PhD
Email
C.Fu@uel.ac.uk
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
29763711
Citation
Mutz J, Edgcumbe DR, Brunoni AR, Fu CHY. Efficacy and acceptability of non-invasive brain stimulation for the treatment of adult unipolar and bipolar depression: A systematic review and meta-analysis of randomised sham-controlled trials. Neurosci Biobehav Rev. 2018 Sep;92:291-303. doi: 10.1016/j.neubiorev.2018.05.015. Epub 2018 May 12.
Results Reference
background
PubMed Identifier
30917990
Citation
Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. 2019 Mar 27;364:l1079. doi: 10.1136/bmj.l1079.
Results Reference
background
PubMed Identifier
33706656
Citation
Woodham R, Rimmer RM, Mutz J, Fu CHY. Is tDCS a potential first line treatment for major depression? Int Rev Psychiatry. 2021 May;33(3):250-265. doi: 10.1080/09540261.2021.1879030. Epub 2021 Mar 11.
Results Reference
background
Learn more about this trial
Transcranial Direct Current Stimulation Therapy for Bipolar Depression
We'll reach out to this number within 24 hrs